

Traditional uses and anticancer potential of the *Combretum* genus: a literature review

ABSTRACT

Background: Cancer incidence is increasing annually in all countries. So, it is nowadays a great burden for the different nations of the world. Research for new therapeutics is becoming an urgent need, particularly for intractable and chemoresistant cancer cases. The solutions can still be found by investigating natural products which are recognized as promising sources of bioactive compounds with a potential for the discovery of new preventive and therapeutic anticancer agents.

Methodology: The present work used databases such as Pubmed, Science Direct and Google scholar to investigate the ethnobotanical uses of some *Combretum* species in the literature. It also allowed us to summarize some pharmacological studies on *Combretum* species.

Result: This review gathers all available traditional uses and cytotoxicity studies of *Combretum* species in the literature. Special focus is given to pharmacological studies highlighting isolated potential anticancer molecules from *Combretum* species that may contribute to improving the health of people suffering from cancer diseases.

Conclusion: The *Combretum* species are widely used in folk medicine for the treatment of several pathologies including cancers. This study is of fundamental importance in highlighting *Combretum* species as a potential source for research of new anticancer compounds.

Keywords: Anticancer potential, *Combretum*, Ethnobotanical uses, Natural product, Traditional medicine.

1. INTRODUCTION

The different cancer diseases continue to have a negative impact on the world. Despite advances in the search for better solutions against the scourge, its incidence is tending to increase. Indeed, statistics show that new cases of cancer increased from 12.7 million in 2008[1] to 14.1 million in 2012[2], then to 18.1 million in 2018[3]. Estimates predict 28.4 million new cases of cancer in 2040 [4]. Cancer caused nearly 10 million deaths in 2020, making cancer one of the leading causes of death worldwide[4]. Cancer is also a major concern for Burkina Faso. In the year 2020, GLOBOCAN estimates revealed 12,045 new cases of cancer, including 8,695 deaths. More than 18,884 new cases are expected for the next five years. Within non-communicable diseases, cancer is the second most causing death in this country after cardiovascular diseases. The most common cancers are breast (16%), liver (10.3%), cervix uteri (9.4%), prostate (8.3%), and bladder (5.5%) [5]. To fight cancer effectively, the Ministry of Health has adopted a strategic plan for 2021 to 2025 in which strong actions against cancer in Burkina Faso have been undertaken. Among other things, there is the strengthening of cancer research, in particular the identification of new antitumor molecules contained in the country's medicinal plants. Burkina Faso has a very rich and varied traditional pharmacopeia[6,7] to which more than 80% of the population has recourse to it for their essential healthcare needs[8].

Medicinal plants have always been a credible alternative for the search for active molecules to counter major public health scourges in the interest of the survival of populations since antiquity[9]. Active molecules of natural origin have long served as a source of therapeutic agents or as a model for the synthesis of derivatives[10]. As part of the fight against cancer, many anti-cancer molecules have been identified from certain medicinal plants. This is the case of vincristine and vinblastine isolated from species of the genus *Catharanthus*; paclitaxel isolated from species of the genus *Taxus*; podophyllotoxin isolated from *Podophyllum emodi*; Colchicine isolated from species of the genus *Colchicum* and many other compounds that are currently used clinically for the treatment of patients with cancer[11]. Given the emergence of cancer resistance forms to current treatments, it is important to always look for new anticancer bioactive

molecules. Ethnobotanical studies show that *Combretum* species are used in the treatment of several pathologies including cancers and their cytotoxicity effects on various cancer cell models have been pharmacologically demonstrated [12,13,14,15]. These diverse therapeutic properties of *Combretum* species are due to the wide variety of secondary metabolites contained in these plants. Indeed, phytochemical analyzes have revealed the presence of many classes of constituents, including triterpenes, flavonoids, lignans, alkaloids, and non-protein amino acids, among others in most species of the *Combretum* genus [16,17,18]. So, species of the *Combretum* genus which are widely used in traditional medicine can be an important source of new anticancer molecules discovery.

The objective of this review was to gather all available traditional uses and cytotoxicity studies of *Combretum* species in the literature. Pharmacological studies highlighting isolated potential anticancer molecules from *Combretum* species was reported as well. This study will contribute to highlight *Combretum* species as a potential source for research of new anticancer compounds.

2. METHODOLOGY

PubMed, Science Direct and Google Scholar databases were used to select the articles. For the search in these databases, the following keywords were used: "*Combretum*," "Traditional uses," "Cytotoxicity" and "cancer". The articles were selected according to these inclusion criteria: made with *Combretum* species; title and summary with traditional uses of *Combretum* species; title and summary with the assessment of cytotoxicity activity of *Combretum* extracts on cancer cell lines; title and summary with the evaluation of cytotoxicity activity of isolated compound from *Combretum* extracts. Exclusion criteria were: duplication of articles and abstracts and full texts irrelevant to the topics in question. Some books and Ph.D. thesis on the topics were also consulted.

3. RESULTS AND DISCUSSION

3.1. Ethnobotanical uses of *Combretum* species

Traditional medicine has a prominent place in the world and specifically in Sub-Saharan developing countries[19]. Indeed, with the resurgence of diseases and the non-accessibility of pharmaceutical drugs, populations living in low-income regions of the world are looking to folk medicine for their healthcare needs[20]. Medicinal plants are mostly used by traditional healers for therapeutic purposes [21]. Ethnobotanical studies have been very important in highlighting some traditional medical knowledge of indigenous peoples and traditional healers which has contributed to the establishment of a list of medicinal plants used in folk medicine as the first line of primary healthcare in the rural community. Such information is useful for researchers in the look for new bioactive compounds, especially anti-cancer agents.

The *Combretum* genus belonging to the Combretaceae family includes nearly 250 plant species among which 12 species are represented in Burkina Faso [22]. Species of *Combretum* are well spread across Sub-Saharan Africa. The geographical distribution of *Combretum* species in Burkina Faso has been investigated by Thiombiano et al. [23], who showed that these species are widespread on the territory. A positive correlation has been observed by Shalukoma et al. [24] between the accessibility of plants and their medicinal uses. Thus, the wide distribution of *Combretum* species across Africa and particularly on the territory of Burkina Faso could explain the medicinal knowledge of these plants and consequently their wide use by populations.

Combretum species are variously used for the treatment of several pathologies. An ethnobotanical study done by Schultz et al. [25] revealed that different parts of *C. molle* are used by traditional healers in Uganda for the treatment of various cancers such as abdominal, bone, cervical, intestinal, liver, skin, throat cancers, and leukemia. Another ethnobotanical investigation realized by Malami et al. [14] points out three *Combretum* species such as *C. micranthum*, *C. Camporum*, and *C. molle* that are used by traditional healers in Nigeria for the treatment of cancers. The roots and leaves of *C. zeyheri* are used by traditional healers in Tanzania for the treatment of cancer [12]. Gade et al. [15] reported the traditional uses of *C. fragrans* in the northern part of Cameroon for the treatment of cancers. Other traditional uses of some *Combretum* species recorded in the literature are shown in table 1.

Comment [a1]: Standardization of referencing methods for scientific sources

Medicinal plants from Burkina Faso are also well used by populations for their healthcare needs. Some ethnobotanical studies allowed to highlight the traditional knowledge of traditional healers in the country. Lingani et al. [26] have listed 61 species of medicinal plants used in the care of kidney diseases in Burkina Faso, among which *C. micranthum* was mentioned. Ouôba et al. [27] reported nearly 134 medicinal recipes from 106 species of medicinal plants from Burkina Faso including *C. molle* for their various medicinal uses. Zerbo et al. [28] showed that 94 species of medicinal plants are used to combat different pathologies in Burkina Faso of which *C. glutinosum*, *C. micranthum*, *C. nigricans*, and *C. paniculatum* are cited. To the best of our knowledge, a study highlighting the ethnobotanical uses of *Combretum* species for cancer treatment in Burkina Faso is not yet reported.

These *Combretum* species could be an important resource for researchers, especially to those from Burkina Faso where the cancer healthcare system and chemotherapy are not accessible, to investigate their anticancer potential and to isolate new anticancer molecules as well.

UNDER PEER REVIEW

Table 1: Traditional uses of some *Combretum* species reported in the literature.

Species	Used parts	Traditional uses	References
<i>C. aculeatum</i> Vent.	Leafy stems, roots	Diarrhea, gonorrhoea, intestinal parasites, colic, dysentery, jaundice, malaria, hypertension, fevers, constipation, fractures, weight delays, hypocalcemia, remineralizing, spasmodic, mental disorders, leprosy, wounds, female sterility, etc.	[29,30]
<i>C. adenogonium</i> Stend. Ex A. Rich.	Leaves	Liver and gallbladder diseases, colds, bronchitis, malaria, anemia, migraine, wounds, amoebic dysentery, diarrhea, urinary disorders, bilious and hematuric fevers, edema, albuminuria, anorexia, cough, severe jaundice, Hypertension, hepatitis, epilepsy, snakebites, asthenia.	[29]
	Bark	Epigastralgia, intestinal parasites, sexual weakness, vomiting, analgesic, aphrodisiac, anthelmintic.	
	Roots	Diseases of the stomach, cough, intestinal parasites, syncope, snake bite, pregnancy bleeding.	
<i>C. apiculatum</i> Sond.	Bark	Aphrodisiac	[31]
<i>C. camporum</i> Engl.	Bark, roots	Cancer	[14]
<i>C. coccineum</i> (Sonn.) Lam.	Leaves	Herbal tea cholagogue	[32]
	Roots and fruits	Anthelmintic	
<i>C. collinum</i> Fresen	Roots	Painful legs, cramps, and joint pains.	[33]
<i>C. crotonoides</i> Hutch et Dalz	Leafy stems	Pneumonia, bronchitis, liver disorders, cholagogue, general fatigue, rheumatism	[29]

Table 1(Continued)

Species	Used parts	Traditional uses	References
<i>C. erythrophyllum</i> (Burch.) Sond.	Leaves, roots, bark	Abdominal pain, sexually transmitted diseases, diarrhea, dysentery, coughs, colds, infertility, sores, and wounds.	[34,35]
<i>C. fragrans</i> F. Hoffm.	Whole plant	Leprosy, coughs, diarrhea, pain and inflammation, jaundice, ulcers, wounds, and cancers.	[12,15,32,36]
	Leaves	Dysentery, burns, and wounds	
	Leafy twigs	Diarrhea,	
	Fruits	Wounds	
	Roots	Diarrhea, pain	
<i>C. glutinosum</i> Perr. ex DC	Leaves	Cholagogues, depurative, diuretic, pectoral, malaria.	[32]
	Leafy twigs	Cholagogues, anemia, childhood gastritis, jaundice, edema, malaria, and various eye conditions.	
	Powdered fruit	Wounds, syphilis.	
<i>C. hartmannianum</i> (Schweinf)	Wood, bark	Febrile, jaundice, bacterial infections, cough, tuberculosis, neoplasia	[37,38,39]
<i>C. hereroense</i> Schinz	Leaves	Abdominal pain, sexually transmitted diseases	[40]
<i>C. imberbe</i> Engl. & Diels	Roots, stem, leaves	Menstruation, stomachache	[31,33]
<i>C. krausii</i> Hochst.	Leaves	Wounds, antiseptic.	[40]
<i>C. leprosum</i> Mart.	Leaves and flowers	Inflammation, pain, treatment of wounds, sedative, diarrhea, expectorant, and antitussive.	[41,42]

Table 1 (Continued)

Species	Used parts	Traditional uses	References
C. micranthum G. Don	Leaves	Diarrhea, dysentery, colic, stomach disorder, digestion disorder, malaria, beriberi, intestinal parasites, asthenia, cough, bronchitis, fevers, lumbago, gallbladder disease, anemia, gonorrhoea, hypertension, mastitis, bilious and hematuric fevers, cancer.	[14,29,32,43]
	Roots	Female sterility, intestinal parasites, syphilis, enuresis, stimulant, constipation, fever gastritis, jaundice, trichocephalosis, cancer.	
	Bark	Contusions, sprains, massage before and after muscular effort, lumbago, cancer.	
	Fruits Seeds	Hypertension, stomatitis, hypotension Candidiasis, thrush, boils abscess, leucorrhoea.	
C. molle G. Don	Leaves, roots, bark	Gonorrhoea, syphilis, influenza, edema, skin diseases and wounds, diarrhea, stomachache, measles, cough, eye pain, asthma, and cancer.	[14,35,40]
C. mucronatum Schumach. & Thonn.	Stem bark	Anthelmintic	[32]
C. nigricans Lepr. ex Guill. et Perr.	Leaves	Wounds and injuries.	[22,28]
	Leafy stems	Hematuria, gastric diseases, malaria, fever, strengthening babies, cancer	
	Bark Roots	Headache, intestinal disorders, rheumatism Mental illness	

Table 1 (Continued)

Species	Part(s) used	Traditional uses	References
<i>C. niroense</i> Aubrev. ex key	Leafy stems	Malaria, dysentery, diarrhea, strengthening babies	[44]
<i>C. paniculatum</i> Vent.	Leaves	Metastasis, neck, head, face and breastcancers	[43]
	Gall	Vomit	[28]
	Leaves	Gastric colic, hernial pain, strengthening, rickets, cough, injuries, hemorrhoids, wounds	
	Roots	Diarrhea, malaria with inflammation of the spleen, wounds	
<i>C. psidioides</i> Welw.	Roots, leaves	Diarrhea, muscle pain, edema.	[12]
<i>C. racemosum</i> P. Beauv.	Whole plant	Anthelmintic, gastrointestinal and genito-urinary infections, hemorrhoid, convulsive coughing, tuberculosis, toothache, and male sterility	[32,45,46]
<i>C. sericeum</i> G. Don	Leaves, rootbark	Hypertension	
	Leafy stems	Malaria, weight delay, open fractures, stomach ache, conjunctivitis, fevers.	[28,47]
<i>C. tomentosum</i> G. Don	Roots	Diarrhea, pneumonia, wounds.	
<i>C. zeyheri</i> Sond.	Bark, leaves	Breast, neck, throat and headCancers	[43]
	Roots, leaves	Diarrhea, cancer	[12]

3.2. Anticancer potential of *Combretum* species

Cancer is a great burden for the different nations of the world. This has led different nations to adopt strategic plans to overcome this pathology. Also, the fact that resistance to available treatments is increasingly appearing motivates researchers to look for new therapeutic molecules and even new therapeutic targets for cancer therapy. Species of the genus *Combretum* could play a key role in the discovery of new therapeutic molecules against cancer. Indeed, some species of this genus are well known for their traditional uses against cancer. Also, several pharmacological studies have been undertaken to elucidate the anticancer properties of plant species from the *Combretum* genus.

Elnour et al. [48] investigated the cytotoxic effect of methanol (80%) extract from the root of *Combretum adenogonium*. They found that the extract inhibits human prostate cancer cell lines (PC-3) with an IC_{50} of 24 $\mu\text{g/mL}$. Fyhrquist et al. [13] showed that the methanol extract from leaves of *Combretum fragrans* inhibits several human cancer cell lines such as T24 (Bladder cancer), Hela (Cervical cancer), and MCF-7 (Breast cancer) with IC_{50} around 4.3 $\mu\text{g/mL}$ for both T24 and Hela cells and 14.6 $\mu\text{g/mL}$ for MCF-7 cells. Balde et al. [49] have highlighted the cytotoxicity of dichloromethane extract from leaves of *Combretum fruticosum* on human cancer cells such as adenocarcinoma human alveolar basal epithelial cells (A549), glioblastoma cells (U373; Hs683), human prostate cancer cells (PC3) and Brain primary metastases cells (Kaka) with IC_{50} of 9 $\mu\text{g/mL}$, 7 $\mu\text{g/mL}$, 8.5 $\mu\text{g/mL}$, 10 $\mu\text{g/mL}$ and 8.3 $\mu\text{g/mL}$ respectively. Moura et al. [50] have isolated trachelogenin from the bark of this plant which highlights cytotoxic properties on human brain cancer cells (SF-295) and human leukemia cells (HL-60). Trachelogenin also presented antiproliferative activity on human colon cancer cells (HCT-116) with an IC_{50} value of 4.8 μM . Makhafole et al. [51] demonstrated that *Combretum microphyllum* has potential antimutagenic activity and protective effects against cancer. Indeed, the crude extract of this plant inhibits the genotoxic end-points induced by 4-nitroquinoline 1-oxide (4NQO), mitomycin-C (MMC), and ethyl methanesulfonate (EMS) in vitro. Isolated compounds n-tetracosanol, eicosanoic acid, and arjunolic acid, with an antimutagenicity of $42 \pm 9.6\%$, $36 \pm 1.5\%$, and $44 \pm 0.18\%$ in *S. typhimurium* TA98. Ethanol (80%) extract of *Combretum paniculatum* has

Comment [a2]: Repeated words without scientific source.

Comment [a3]: Standardization of referencing methods for scientific sources

presented a potent cytotoxic effect on HeLa cancer cells at 500 µg/mL. The extract inhibits almost 70% of the growth of this cancer cell line [52]. Jurkat cells exposed to *Combretum platypetalum* extract at 31,25 µg/ml during 72 hours show a significant reduction of cell viability of this cell line [53]. Ethanol extract from leaves of *Combretum quadrangulare* presented a cytotoxic effect on A549 cancer cells after 48 hours of treatment with an IC₅₀ of 136.1 µg/mL [54]. Santos et al. [55] have highlighted the antiproliferative activity of ethyl acetate extract from leaves of *Combretum rupicola*. The extract showed significant anticancer activities against four cell lines and the most significant activity was observed against MCF-7 cells (65.9 µg/mL). All these results contribute to highlighting the anticancer potential of *Combretum* species and in the same way justify their uses in traditional medicine for cancer treatment.

3.3. Potential anticancer compounds isolated from *Combretum* species

Many potential anticancer compounds have been isolated from *combretum* species. The cytotoxicity of some important isolated compounds is presented in table 2 and their structures are shown in Figure 1. Few of these compounds have been investigated in depth for preclinical studies. The myricitrin isolated from *C. lanceolatum* proved to be most effective in inhibiting the growth of leukemic HL-60 cells. The mechanism of this inhibition is through the inhibition of the topoisomerase II α [56]. The trachelogenin compound isolated from *C. fruticosum* induced autophagy cell death in human colon cancer cells (HCT-116) with LC3 activation and altered the expression levels of Beclin-1 [50]. The triterpenoid (1-O-[α -L-(rhamnopyranosyl)]-23-acetoxy-3 β -acetyl-imberbic acid) isolated from *C. Sundaicum* inhibited KB, MCF7, and HCT-116 cells growth by binding to Bcl-xL protein [57]. The pentacyclitriterpene (3 β , 6 β , 16 β -trihydroxylup-20(29)-ene) isolated from *C. leprosum* induced apoptosis in MCF7 cells by increasing levels of both cleaved caspase-9 and intracellular ROS [58]. Among isolated compounds from *Combretum* species, Combretastatins were the most subject to research. They are first isolated from the South African *Combretum caffrum* species [59]. Other *Combretum* species also contain

these molecules [60,61]. Combretastatins are simple compounds formed of two phenyl rings linked by a chain of two carbon atoms. They consist of several series belonging to the stilbenoid class of compounds [62]. Several studies have been undertaken to highlight the anticancer properties of these compounds [63,64,65]. Combretastatins belonging to the A and B series present potent anticancer activity with the combretastatin A4 molecule being the most potent due to its broad-spectrum cytotoxicity against a variety of tumor cells [66]. It has been demonstrated that Combretastatin A4 can induce cell cycle arrest at M-phase and apoptosis in various cancer cells through a mechanism of action involving inhibition of tubulin polymerization [64,65]. It has also been revealed that combretastatin A4 can reverse daunorubicin resistance acquisition in the P-388 cell line [67]. This proves that the molecule could play an important role in the treatment of certain resistant forms of tumors. The cis isomer of this molecule is the active form while the trans isomer is inactive [63]. The cis isomer can spontaneously isomerize into the trans isomer. This problem of isomerism added to its low solubility and its poor bioavailability has led to the development of analogs such as combretastatin A4 phosphate which is water-soluble, bioavailable, and biologically active [68]. Combretastatin A4 phosphate undergoes clinical trials as an anticancer agent for the treatment of solid cancers [69,70].

Table 2: Cytotoxicity (IC₅₀) of isolated compounds from *Combretum* species on some cancer cell models.

Species	Plant part	Compounds	Cell lines	Histotype	IC ₅₀	References
<i>Combretum caffrum</i> (Eckl. and Zeyh.) Kuntze	Twigs and leaves	(1) Combretastatin A4	P-388	murine lymphocytic leukemia	0.011 µg/mL	[59]
<i>Combretum fragrans</i> F. Hoffm.	Leaves	(2) Combretin A	MCF-7	Breast adenocarcinoma	16.1 µg/mL	[15,36]
			U87 PC-3	Glioblastoma Prostate adenocarcinoma	29.3 µM 22.57 µM	
		(3) Combretin B	MCF-7	Breast adenocarcinoma	<1 µg/mL	[36]
		(4) Cirsilineol	U87 PC-3	Glioblastoma Prostate adenocarcinoma	65.46 µM 30.46 µM	[15]
<i>Combretum racemosum</i> P. Beauv.	Roots	(5) 3-O-β-acetyl-ursolic acid	HL-60	Leukemia	14.5 µM	[71]
			K562	Leukemia	50.0 µM	
		(6) Betulinic acid	HL-60 K562	Leukemia Leukemia	35 µM >50 µM	[71]
		(7) Quadranoside II	HL-60 K562	Leukemia Leukemia	13 µM 44.0 µM	[71]
<i>Combretum griffithii</i> Heurck & Müll.	stems	(8) 1-(5-hydroxy-2,4-dimethoxyphenyl)-3-(4-	KB	Cervical adenocarcinoma	24.63 µM	[72]

		hydroxy-3-methoxyphenyl)propane	MCF-7	Breast adenocarcinoma	23.12 μ M	
			NCI-H18	Small cell lung cancer	34.65 μ M	
		(9) (2S)-3',4'-dihydroxy-5,7-dimethoxyflavan	KB (Hela derivative)	Cervical cancer	31.82 μ M	[72]
			MCF-7	Breast adenocarcinoma	49.15 μ M	
			NCI-H18	Small cell lung cancer	10.41 μ M	
Combretum leprosum Mart.	Flowers	(10) 3 β ,6 β ,16 β -Trihydroxylup-20(29)-ene	MCF-7	Breast adenocarcinoma	1.36 μ g/mL	[58]
			HepG2	Hepatoma	6.50 μ g/mL	
			T24	Bladder carcinoma	5.55 μ g/mL	
			HCT-116	Colorectal carcinoma	7.05 μ g/mL	
			HT-29	Colorectal adenocarcinoma	8.0 μ g/mL	
			CACO-2	Colorectal adenocarcinoma	8.55 μ g/mL	
Combretum quadrangulare Kurz	Leaves	(11) Methyl quadrangularate D	Colon 26-L5	Murine colon cancer	5.42 μ M	[73]
			HT-1080	Fibrosarcoma	40.0 μ M	
			HeLa	Cervical carcinoma	50.9 μ M	
			A-549	Lung adenocarcinoma	63.5 μ M	
		(12) Methyl	Colon 26-L5	Murine colon cancer	9.54 μ M	[73]

		quadrangularate B			
			HT-1080	Fibrosarcoma	53.3µM
			HeLa	Cervical carcinoma	56.0µM
			A-549	Lungadenocarcinoma	>100.0µM
		(13) Combretic acid C	K562	Leukemia	9.7 µM [74]
		(14) Kamatakenin	Colon 26-L5	Murine colon cancer	3.0 µM [75]
			HT-1080	Fibrosarcoma	3.2 µM
			HeLa	Cervical carcinoma	10.6 µM
			A-549	Lungadenocarcinoma	40.1 µM
		(15) Isokaempferide	Colon 26-L5	Murine colon cancer	4.5 µM [75]
			HT-1080	Fibrosarcoma	0.8 µM
			HeLa	Cervical carcinoma	8.2 µM
			A-549	Lung adenocarcinoma	39.2 µM
		(16) 5,7,4'-trihydroxy-3,3'-dimethoxyflavone	Colon 26-L5	Murine colon cancer	1.8 µM [75]
			HT-1080	Fibrosarcoma	1.5 µM
			HeLa	Cervical cancer	6.8 µM
			A-549	Lung adenocarcinoma	95.3 µM
		(17) 5,4'-dihydroxy-3,7,3'-trimethoxyflavone	Colon 26-L5	Murine colon cancer	5.2 µM [75]
			HT-1080	Fibrosarcoma	3.5 µM
			HeLa	Cervical carcinoma	38.4 µM
			A-549	Lung adenocarcinoma	41.9 µM
Combretum nigricans Lepr. ex Guill. et Perr.	Leaves	(18) 20,24-epoxy-11 α ,25-dihydroxy-dammar-3-one	U-373	Glioblastoma	31.6 µg/mL [76]


			HCT-15	Colon adenocarcinoma	30.4 µg/mL	
			A-549	Lung adenocarcinoma	29.7 µg/mL	
		(19) 11 α -acetoxy-20,24-epoxy-25-hydroxy-dammar-3-one	J82	Bladder carcinoma	29.6 µg/mL	
			U-373	Glioblastoma	51.7 µg/mL	[76]
			HCT-15	Colon adenocarcinoma	88.4 µg/mL	
			A549	Lung adenocarcinoma	>100 µg/mL	
			J82	Bladder carcinoma	80.6 µg/mL	
<i>Combretum oliviforme</i> Chao	Leaves	(20) 23-acetoxy-3 β -acetylimberbic acid-29-methyl ester	SPC-A1	Lung cancer	1.09 µM	[77]
			SGC-7901	Gastric cancer	0.69 µM	
			K562	Leukemia	2.10 µM	
		(21) 23-O-[α -L-rhamnopyranosyl]-1,3 β -diacetylimberbic acid	SPC-A1	Lung cancer	25.20 µM	[77]
			SGC-7901	Gastric carcinoma	5.44 µM	
			K562	Leukemia	2.38 µM	
<i>Combretum fruticosum</i> (Loefl.) Stuntz	Stalks	(22) (-)-Trachelogenin	HL-60	Leukemia	32.4 µM	[50]
			OVCAR-8	Ovarian carcinoma	3.5 µM	
			HCT-116	Colorectal carcinoma	1.9 µM	

			HCT-8	Ileocecal adenocarcinoma	5.2 μ M	
			PC-3 SF295	Prostate cancer Glioblastoma	15 μ M 0.8 μ M	
<i>Combretum sundaicum</i> Miq.	Leaves and flowers	(23) 1-o-[α -L-rhamnopyranosyl]-23-acetoxy-3 β -acetylimberbic acid-29-methyl ester	KB	Cervical adenocarcinoma	0.9 μ M	[57]
			HCT-116 MCF-7	Colorectal carcinoma Breast adenocarcinoma	0.3 μ M 0.6 μ M	
<i>Combretum platypetalum</i> Welw. ex M.A. Lawson	Leaves	(24) 3-o-(β -D-glucopyranosyl)-5,7,3',4',5'-pentahydroxyflavone	Jurkat T	Leukemia	3.98 μ g/mL	[78]
		(25) 3-o-(α -L-rhamnopyranosyl)-5,7,3',4',5'-pentahydroxyflavone	Jurkat T	Leukemia	14.18 μ g/mL 19.33 μ g/mL	[78]
			HL-60	Leukemia	28.7 μ g/mL	
<i>Combretum Lanceolatum</i> Pohl.	Leaves and branches	(26) myricetin	MCF7	Breast adenocarcinoma	158.4 μ M	[56]
			PC-3	Prostate cancer	182.8 μ M	

			HT-29	Colon adenocarcinoma	95 μ M	
			786-0	Kidney carcinoma	124.6 μ M	
			HL-60	Leukemia	53.4 μ M	
<i>Combretum laxum</i> Jacq.	Roots	(27) 4'-hydroxy-3,3',4-trimethoxy-5-(3,4,5-trimethoxyphenoxy)-bibenzyl	MCF-7	Breast adenocarcinoma	72.69 μ M	[79]
			NCI/ADR-RES	Ovary carcinoma, multidrug-resistant	32.09 μ M	
		(28) 2,7-dihydroxy-4,6-dimethoxyphenanthrene	786-0	Kidney carcinoma	73.26 μ M	[79]
			NCI/ADR-RES	Ovary carcinoma, multidrug-resistant	83.99 μ M	
		(29) 2,6-dihydroxy-3,4,7-trimethoxyphenanthrene	786-0	Kidney carcinoma	64.27 μ M	[79]
		(30) 6-methoxycoelonin	MCF-7	Breast adenocarcinoma	46.99 μ M	[79]
			UACC-62	Human melanoma	2.59 μ M	
			NCI/ADR-RES	Ovary carcinoma, multidrug-resistant	58.83 μ M	
		(31) 2,6-dihydroxy-3,4,7-trimethoxy-9,10-dihydrophenanthrene	786-0	Kidney carcinoma	56.98 μ M	
			MCF-7	Breast adenocarcinoma	42.01 μ M	[79]
<i>Combretum inflatum</i> Jongkind	Leaves	(32) Combretaside G	NCI-H460	Lung carcinoma	3.9 μ M	[80]

Combretum mellifluum Eichler	Roots and Leaves	(33) Tetrahydrofuran lignan	HT-29	Colon adenocarcinoma	3.9 μ M	[81]
		(34) 2,3-seco-lup- 20(29)-en-2,3-dioic acid	786-0	Kidney carcinoma	0.5 μ M	[81]
			HT-29	Colon adenocarcinoma	2.9 μ M	

UNDER PEER REVIEW






Figure 1: Chemical structures of some important cytotoxic isolated compounds from *Combretum* species.

The different numbers (1-34) correspond to the compound names in table 2.




Figure 1 (Continued)

4. CONCLUSION AND PERSPECTIVES

In this review, we discussed the traditional uses of *Combretum* species reported in some ethnobotanical studies over the world with special emphasis on their anticancer uses. We also highlighted several pharmacological studies realized on *Combretum* species which revealed their cytotoxicity activities on some cancer cell models pointing out the anticancer potential of these plant species. Finally, some potential anticancer compounds isolated from *Combretum* species were reported as well. This proves that *Combretum* species could be an important resource for researchers to look for new anticancer molecules that may contribute to the fight against cancers. In perspectives, ethnobotanical studies must be undertaken on *combretum* species especially the 12 *Combretum* species present in Burkina Faso to highlight their anticancer uses and correlate this finding to clinical efficacy which will be evaluated by controlled clinical studies.

CONSENT: It is not applicable

REFERENCES

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin.*2011;61(2):69-90. doi: 10.3322/caac.20107.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.*(2015);65(2):87-108. doi: 10.3322/caac.21262.
3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality

worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2018;68(6):394-424. doi: 10.3322/caac.21492.

4. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.*2021;71(3):209-249. doi: 10.3322/caac.21660.
5. GLOBOCAN, 2020. BURKINA FASO. <https://gco.iarc.fr/today/data/factsheets/populations/854-burkina-faso-factsheets.pdf> (Accessed on 15 Dec. 2022)
6. Beiersmann C, Sanou A, Wladarsch E, De Allegri M, Kouyaté B, Müller O. Malaria in rural Burkina Faso: local illness concepts, patterns of traditional treatment and influence on health-seeking behaviour. *Malar J.* 2007;6:106. doi: 10.1186/1475-2875-6-106.
7. Nadembega P, Boussim JI, Nikiema JB, Poli F, Antognoni F. Medicinal plants in Baskoure, Kourittenga Province, Burkina Faso: an ethnobotanical study. *J Ethnopharmacol.*2011;133(2):378-395. doi: 10.1016/j.jep.2010.10.010.
8. Jansen O, Angenot L, Tits M, Nicolas JP, De Mol P, Nikiéma J-B, Frédérick M. Evaluation of 13 selected medicinal plants from Burkina Faso for their antiplasmodial properties. *J Ethnopharmacol.* 2010;130:143-150.doi: 10.1016/j.jep.2010.04.032
9. Sofowora A, Ogunbodede E, Onayade A. The role and place of medicinal plants in the strategies for disease prevention. *Afr J Tradit Complement Altern Med.*2013;10(5):210-229. doi: 10.4314/ajtcam.v10i5.2.
10. Dehelean CA, Marcovici I, Soica C, Mioc M, Coricovac D, Iurciuc S et al. Plant-derived anticancer compounds as new perspectives in drug discovery and alternative therapy. *Molecules*2021;26(4):1109. <https://doi.org/10.3390/molecules26041109>.
11. Lichota A, Gwozdziński K. Anticancer Activity of natural compounds from plant and marine environment. *Int J Mol Sci.*2018;19(11):3533. doi: 10.3390/ijms19113533.
12. Fyhrquist P, Mwasumbi L, Haeggström CA, Vuorela H, Hiltunen R, Vuorela P. Ethnobotanical and antimicrobial investigation on some species of

- Terminalia* and *Combretum* (Combretaceae) growing in Tanzania. J Ethnopharmacol.2002;79(2):169-177. doi: 10.1016/s0378-8741(01)00375-0.
13. Fyhrquist P, Mwasumbi L, Vuorela P, Vuorela H, Hiltunen R, Murphy C et al. Preliminary antiproliferative effects of some species of *Terminalia*, *Combretum* and *Pteleopsis* collected in Tanzania on some human cancer cell lines. Fitoterapia2006;77(5):358-366. doi: 10.1016/j.fitote.2006.05.017.
 14. Malami I, Jagaba NM, Abubakar IB, Muhammad A, Alhassan AM, Waziri PM et al. Integration of medicinal plants into the traditional system of medicine for the treatment of cancer in Sokoto State, Nigeria. Heliyon2020;6(9):e04830. doi: 10.1016/j.heliyon.2020.e04830.
 15. Gade IS, Chadeneau C, Simo RT, Talla E, Atchade ADT, Seité P et al. A new phenyl alkyl ester and a new combretin triterpene derivative from *Combretum fragrans* F. Hoffm (Combretaceae) and antiproliferative activity. Open Chemistry2020;18(1),1523-1531. doi:10.1515/chem-2020-0167
 16. Couliadiati TH, Millogo-Koné H, Lamien-Meda A, Yougbaré-Ziébrou M, Millogo-Rasolodimby J, Nacoulma OG. Antioxidant and antibacterial activities of two *Combretum* species from Burkina Faso. Res J Med Plants 2011;5:42-53.
 17. Dawe A, Saotoing P, Tsala DE, Habtemariam S. Phytochemical constituents of *Combretum loefl.* (Combretaceae). Pharmaceutical Crops2013;4:38-59.
 18. Bantho S, Naidoo Y, Dewir YH, Bantho A, Murthy HN. Chemical composition of *Combretum erythrophyllum* leaf and stem bark extracts. Horticulturae2022;8:755. <https://doi.org/10.3390/horticulturae8080755>
 19. Moyo M, Aremu AO, Van Staden J. Medicinal plants: An invaluable, dwindling resource in sub-Saharan Africa. J Ethnopharmacol.2015;174:595-606. doi: 10.1016/j.jep.2015.04.034.
 20. Abdullahi AA. Trends and challenges of traditional medicine in Africa. Afr J Tradit Complement Altern Med.2011;8:115-123. doi: 10.4314/ajtcam.v8i5S.5.
 21. Benoît É. Les changements climatiques : vulnérabilité, impacts et adaptation dans le monde de la médecine traditionnelle au Burkina Faso. Vertigo2008;8(1) DOI : 10.4000/vertigo.1467. French

22. Thiombiano A. Les Combretaceae du Burkina Faso : taxonomie, écologie, dynamique et régénération des espèces. Thèse de doctorat d'État, Université de Ouagadougou, Burkina Faso, 290 p.2005French
23. Thiombiano A, Schmidt M, Kreft H, Guinko S. Influence du gradient climatique sur la distribution des espèces de Combretaceae au Burkina Faso (Afrique de l'Ouest). *Candollea*2006;61:189-213. French
24. Shalukoma C, Bogaert J, Duez P, Stévigny C, Pongombo C, Visser M. Les plantes médicinales de la région montagneuse de Kahuzi-Biega en République Démocratique du Congo : utilisation, accessibilité et consensus des tradipraticiens. *Bois et Forêts des tropiques*2015;326:43-55. French
25. Schultz F, Anywar G, Wack B, Quave CL, Garbe LA. Ethnobotanical study of selected medicinal plants traditionally used in the rural Greater Mpigi region of Uganda. *J Ethnopharmacol.*2020;256:112742. doi: 10.1016/j.jep.2020.112742.
26. Lingani A, Lompo LF, Guissou IP, Nikiema JB. Médecine traditionnelle et maladies des reins au Burkina Faso [Traditional medicine in kidney diseases in Burkina Faso]. *NephrolTher.*2010;6(1):35-39. doi: 10.1016/j.nephro.2009.07.011. French
27. Ouôba P, Lykke AM, Boussim J, Guinko S. La flore médicinale de la forêt classée de Niangoloko (Burkina Faso). *Etudes florég Burkina Faso* 2006;10:5-16 French
28. Zerbo P, Millogo-Rasolodimby J, Nacoulma OG, Van Damme P. Plantes médicinales et pratiques médicales au Burkina Faso : cas des Sanan. *Bois et Forêts des Tropiques*2011;307(1):41-53. French
29. NACOULMA OG. Plantes médicinales et pratiques médicales traditionnelles au Burkina Faso : cas du plateau central. Thèse de doctorat d'État, Faculté des sciences et techniques, Université de Ouagadougou, Burkina Faso, tome 1, 320 p., tome 2, 285 p.1996 French
30. Arbonnier M. Arbres, arbustes et lianes des Zones sèches d'Afrique de l'Ouest. Ed. ISBN CIRAD, Pont-sur-Yonne, 392, 574p.2002 French
31. Bruschi P, Morganti M, Mancini M, Signorini MA. Traditional healers and laypeople : a qualitative and quantitative approach to local knowledge on medicinal plants in muda (Mozambique). *J Ethnopharmacol.* 2011;138:543-563.

32. Boulard B. Plantes médicinales du monde : croyances et réalités. Ed. ESTEM, ISBN 2843711177 Paris, 660p.2001 French
33. Tshikalange TE, Mophuting BC, Mahore J, Winterboer S, Lall N. An Ethnobotanical study of medicinal plants used in villages under Jongilanga tribal council, Mpumalanga, South Africa. *Afr J Tradit Complement Altern Med.*2016;13(6):83-89.
34. Martini ND, Katerere DRP, Eloff JN. Biological activity of five antibacterial flavonoids from *Combretum erythrophyllum* (Combretaceae). *J Ethnopharmacol.* 2004;93:207-212.
35. Cock IE, Van Vuuren SF. A comparison of the antimicrobial and toxicity of six *Combretum* and two *Terminalia* species from southern Africa. *Pharmacognosy Magazine*2015;11(41):208-218.
36. Mbiantcha M, Almas J, Dawe A, Faheem A, Sidra Z. Analgesic, anti-inflammatory and anticancer activities of Combretin A and Combretin B isolated from *Combretum fragrans* F. HOFFM (Combretaceae) leaves. *Inflammopharmacology*2018;26(6):1429-1440. doi: 10.1007/s10787-017-0421-5.
37. Mohieldin EAM, Muddathir AM, Mitsunaga T. Inhibitory activities of Sudanese medicinal plants on *Porphyromonas gingivalis* and matrix metalloproteinase-9 and isolation of bioactive compounds from *Combretum hartmannianum* (Schweinf) bark. *BMC Complement Altern Med.*2017;17(1):224. doi: 10.1186/s12906-017-1735-y.
38. Hassan LE, Ahamed MB, Majid AS, Baharetha HM, Muslim NS, Nassar ZD et al. Correlation of antiangiogenic, antioxidant and cytotoxic activities of some Sudanese medicinal plants with phenolic and flavonoid contents. *BMC Complement Altern Med.*2014;14:406. doi: 10.1186/1472-6882-14-406.
39. Salih EYA, Julkunen-Tiitto R, Luukkanen O, Fahmi MKM, Fyrquist P. Hydrolyzable tannins (ellagitannins), flavonoids, pentacyclic triterpenes and their glycosides in antimycobacterial extracts of the ethnopharmacologically selected Sudanese medicinal plant *Combretum hartmannianum* Schweinf. *Biomed Pharmacother.*2021;144:112264. doi: 10.1016/j.biopha.2021.112264.

40. Martini ND, Eloff JN. The preliminary isolation of several antibacterial compounds from *Combretum erythrophyllum* (Combretaceae). *J Ethnopharmacol.* 1998;62:255-263.
41. Horinouchi CD, Mendes DA, SoleyBda S, Pietrovski EF, Facundo VA, Santos AR et al. *Combretum leprosum* Mart. (Combretaceae) : potential as an antiproliferative and anti-inflammatory agent. *J Ethnopharmacol.* 2013;145(1):311-319. doi: 10.1016/j.jep.2012.10.064.
42. Lacouth-Silva F, Xavier CV, Sutúbal SDS, Pontes AS, Nery NM, de Castro OB et al. The effect of 3 β , 6 β , 16 β -trihydroxylup-20(29)-ene lupine compound isolated from *Combretum leprosum* Mart. On peripheral blood mononuclear cells. *BMC Complement Altern Med.* 2015;15(1):420. doi: 10.1186/s12906-015-0948-1.
43. Abubakar IB, Ukwuani-Kwaja AN, Garba AD, Singh D, Malami I, Salihu TS et al. Ethnobotanical study of medicinal plants used for cancer treatment in Kebbi state, North-west Nigeria. *Acta Ecologica Sinica* 2020;40(4):306-314.
44. Coulidiati TH, Millogo-Koné H, Lamien-Meda A, Lamien CE, Lompo M, Kiendrébégo M et al. Antioxidant and antibacterial activities of *Combretum nioroense* Aubrév. Ex Keay (Combretaceae). *Pak J Biol Sci.* 2009;12(3):264-269. doi: 10.3923/pjbs.2009.264.269.
45. Okwuosa C, Unekwe P, Nwobobo E, Chilaka K. The anti-ulcer activities of leaf extracts of *Combretum racemosum* (family: combretaceae). *Journal of Biomedical Investigation* 2006;4(1):9-14. doi: 10.4314/jbi.v4i1.30408
46. Manga FN, Khattabi CE, Fontaine J, Berkenboom G, Duez P, Nzunzu JL et al. Vascular effects and antioxidant activity of two *Combretum* species from Democratic Republic of Congo. *J Ethnopharmacol.* 2012;142(1):194-200.
47. Sini JM, Umar IA, Anigo KM, Stancheva I, Bage EN, Mohammed R. Antidiarrhoeal activity of aqueous extract of *Combretum sericeum* roots in rats. *Afr J Biotech.* 2008;7(17):3134-3137.
48. Elnour MA, Penech F, Ibrahim S, Khalid A. *Combretum adenogonium* induce anticancer and antioxidant effects in prostate cancer cell line. *Significances Bioengineering & Biosciences* 2018;2(2):138-140. doi: 10.31031/SBB.2018.02.000534

49. Balde ES, Camara AK, Traoré MS, Baldé NM, Megalizzi V, Pieters L et al. The hypoglycemic and cytotoxic activity of the leaf extract of *Combretum glutinosum* Perr ex DC. *J PharmacognPhytochem.* 2019;8(4):2230-2237.
50. Moura AF, Lima KSB, Sousa TS, Marinho-Filho JDB, Pessoa C, Silveira ER et al. In vitro antitumor effect of a lignan isolated from *Combretum fruticosum*, trachelogenin, in HCT-116 human colon cancer cells. *Toxicol In Vitro* 2018;47:129-136. doi: 10.1016/j.tiv.2017.11.014.
51. Makhafola TJ, Elgorashi EE, McGaw LJ, Awouafack MD, Verschaeve L, Eloff JN. Isolation and characterization of the compounds responsible for the antimutagenic activity of *Combretum microphyllum* (Combretaceae) leaf extracts. *BMC Complement Altern Med.* 2017;17(1):446. doi: 10.1186/s12906-017-1935-5.
52. Sowemimo A, van de Venter M, Baatjies L, Koekemoer T. Cytotoxic activity of selected Nigerian plants. *Afr J Tradit Complement Altern Med.* 2009;6(4):526-528. doi: 10.4314/ajtcam.v6i4.57186.
53. Chiramba O, Mukanganyama S. Cytotoxic effects of *Combretum platypetalum* Welw. ex M.A. Lawson subsp. oatesii (Rolfe) Exell (Combretaceae) leaf extracts on Jurkat T-cells and reversal of effects by reduced glutathione. *Journal of Biologically Active Products from Nature* 2016;6(3):250-265. doi: 10.1080/22311866.2016.1232626.
54. Chittasupho C, Athikomkulchai S. Nanoparticles of *Combretum quadrangulare* leaf extract induce cytotoxicity, apoptosis, cell cycle arrest and anti-migration in lung cancer cells. *Journal of Drug Delivery Science and Technology* 2018;45:378-387.
55. Santos SN, Kavamura V, Castanha RF, Andreote FD, Carvalho JE, Queiroz SCN et al. Antitumoral, antioxidant and antimicrobial molecules from *combretum rupicola*. *Int J Pharma Bio Sci.* 2013;4(1):422-428.
56. Perdomo RT, Defende CP, da Silva Mirowski P, Freire TV, Weber SS, Garcez WS et al. Myricitrin from *Combretum lanceolatum* exhibits inhibitory effect on DNA-topoisomerase type II α and protective effect against in vivo doxorubicin-induced mutagenicity. *J Med Food.* 2021;24(3):273-281. doi: 10.1089/jmf.2020.0033.
57. Litaudon M, Jolly C, Le Callonec C, Cuong DD, Retailleau P, Nosjean O et al. Cytotoxic pentacyclic triterpenoids from *Combretum sundaicum* and

- Lantana camara as inhibitors of Bcl-xL/BakBH3 domain peptide interaction. *J Nat Prod.*2009;72(7):1314-1320. doi: 10.1021/np900192r.
58. Viau CM, Moura DJ, Facundo VA, Saffi J. The natural triterpene 3 β ,6 β ,16 β -trihydroxy-lup-20(29)-ene obtained from the flowers of *Combretum leprosum* induces apoptosis in MCF-7 breast cancer cells. *BMC Complement Altern Med.*2014;14:280. doi: 10.1186/1472-6882-14-280.
59. Pettit GR, Cragg GM, Singh SB. Antineoplastic agents, 122. constituents of *Combretumcaffrum*. *J Nat Prod.* 1987;50(3):386-391.
60. Fyhrquist P, Salih EYA, Helenius S, Laakso I, Julkunen-Tiitto R. HPLC-DAD and UHPLC/QTOF-MS analysis of polyphenols in extracts of the african species *Combretumpadoides*, *C. zeyheri* and *C. psidioides* related to their antimycobacterial activity. *Antibiotics (Basel)*2020;9(8):459. doi: 10.3390/antibiotics9080459.
61. Anokwuru CP, Chen W, van Vuuren S, Combrinck S, Viljoen AM. Bioautography-guided HPTLC-MS as a rapid hyphenated technique for the identification of antimicrobial compounds from selected South African Combretaceae species. *Phytochem Anal.*2022;33(8):1177-1189. doi: 10.1002/pca.3167.
62. Karatoprak GŞ, KüpeliAkkol E, Genç Y, Bardakci H, Yücel Ç, Sobarzo-Sánchez E. Combretastatins: An overview of structure, probable mechanisms of action and potential applications. *Molecules*2020;25(11):2560. doi: 10.3390/molecules25112560.
63. Lawrence NJ, Ghani FA, Hepworth LA, Hadfield JA, McGown AT, Pritchard RG. The synthesis of (E) and (Z)-combretastatins A-4 and a phenanthrene from *Combretum caffrum*. *Synthesis*1999;9:1656-1660.
64. Vitale I, Antoccia A, Cenciarelli C, Crateri P, Meschini S, Arancia G et al. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. *Apoptosis*2007;12(1):155-166. doi: 10.1007/s10495-006-0491-0.
65. Barnes NG, Parker AW, Ahmed Mal Ullah AA, Ragazzon PA, Hadfield JA. A 2-step synthesis of Combretastatin A-4 and derivatives as potent tubulin assembly inhibitors. *Bioorg Med Chem.* 2020;28(19):115684. doi: 10.1016/j.bmc.2020.115684.

66. Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garia-Kendall D. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A4. *Experientia*1989;45:205-211. doi: 10.1007/BF01954881.
67. McGown AT, Fox BW. Differential cytotoxicity of Combretastatins A1 and A4 in two daunorubicin-resistant P388 cell lines. *Cancer ChemotherPharmacol.* 1990;26:79-81. <https://doi.org/10.1007/BF02940301>
68. West CM, Price P. Combretastatin A4 phosphate. *Anticancer Drugs*2004;15(3):179-187. doi: 10.1097/00001813-200403000-00001.
69. Liu P, Qin Y, Wu L, Yang S, Li N, Wang H et al. A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections. *Anticancer Drugs*2014;25(4):462-471. doi: 10.1097/CAD.0000000000000070
70. Grisham R, Ky B, Tewari KS, Chaplin DJ, Walker J. Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management. *GynecolOncol Res Pract.*2018;5:1. doi: 10.1186/s40661-017-0058-5.
71. Gossan DPA, Magid AA, Yao-Kouassi PA, Josse J, Gangloff SC, Morjani H et al. Antibacterial and cytotoxic triterpenoids from the roots of *Combretum racemosum*. *Fitoterapia*2016;110:89-95. <https://doi.org/10.1016/j.fitote.2016.03.002>.
72. Moosophon P, Kanokmedhakul S, Kanokmedhakul K, Buayairaksa M, Noichan J, Poopasit K. Antiplasmodial and cytotoxic flavans and diarylpropanes from the stems of *Combretum griffithii*. *J Nat Prod.*2013;76(7):1298-1302. doi: 10.1021/np400266h.
73. Banskota AH, Tezuka Y, Phung LK, Tran KQ, Saiki I, Miwa Y et al. Cytotoxic cycloartane-type triterpenes from *Combretum quadrangulare*. *Bioorg Med ChemLett.*1998;8(24):3519-3524. doi: 10.1016/s0960-894x(98)00644-1.
74. Vo TS, Nguyen HH, Nguyen TP, Tran TM, Bui XH, Dinh MH et al. Cycloartanes from leaves of *Combretum quadrangulare* growing in Vietnam. *Nat Prod Res.* 2022;1-8. doi: 10.1080/14786419.2022.2045489.
75. Banskota AH, Tezuka Y, Tran KQ, Tanaka K, Saiki I, Kadota S. Methyl quadrangularates A-D and related triterpenes from *Combretum quadrangulare*. *Chem Pharm Bull (Tokyo)*2000;48(4):496-504. doi: 10.1248/cpb.48.496.

76. Simon G, Dewelle J, Nacoulma O, Guissou P, Kiss R, Dalozé D et al. Cytotoxic pentacyclic triterpenes from *Combretum nigricans*. *Fitoterapia*2003;74(4):339-344. doi: 10.1016/s0367-326x(03)00046-7.
77. Wu XP, Han CR, Chen GY, Yuan Y, Xie JY. Cytotoxic pentacyclic triterpenoids from *Combretum oliviforme*. *Nat Prod Commun*.2010;5(7):1027-1030.
78. Wende M, Sithole S, Chi GF, Stevens MY, Mukanganyama S. The effects of combining cancer drugs with compounds isolated from *Combretum zeyheri* Sond. and *Combretum platypetalum* Welw. ex M.A. Lawson (Combretaceae) on the viability of Jurkat T cells and HL-60 cells. *Biomed Res Int*. 2021. doi: 10.1155/2021/6049728.
79. Bisoli E, Freire TV, Yoshida NC, Garcez WS, Queiróz LMM, Matos MFC et al. Cytotoxic phenanthrene, dihydrophenanthrene, and dihydrostilbene derivatives and other aromatic compounds from *Combretum laxum*. *Molecules*2020;25(14):3154. doi: 10.3390/molecules25143154.
80. Williams RB, Norman VL, Goering MG, O'Neil-Johnson M, Eldridge GR, Starks CM. Acetylated dammarane-type bisdesmosides from *Combretum inflatum*. *J Nat Prod*.2013;76(9):1592-1597. doi: 10.1021/np4002652.
81. Mirowski PDS, Ojeda M, Kollet LG, Freire TV, Pott A, Garcez WS et al. Selective tumor cell growth inhibition by lignans and a seco-triterpenoid from *Combretum mellifluum*. *Nat Prod Res*.2022;10:1-8. doi: 10.1080/14786419.2021.2024823.